{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:07:52Z","timestamp":1790989672525,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd014541","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000}}],"reference-count":124,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014541.pub2","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T06:43:27Z","timestamp":1733294607000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients"],"prefix":"10.1002","volume":"2024","author":[{"given":"Ahmed A","family":"Kolkailah","sequence":"additional","affiliation":[{"name":"Division of Cardiology; University of Texas Southwestern Medical Center; Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahaa","family":"Abdelghaffar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine,  Heart, Vascular and Thoracic Institute; Cleveland Clinic Florida; Weston FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farida","family":"Elshafeey","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; Ain Shams University; Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Magdy","sequence":"additional","affiliation":[{"name":"Department of Neurology; Ain Shams University; Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menna","family":"Kamel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; Ain Shams University; Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmeen","family":"Abuelnaga","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; Ain Shams University; Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf F","family":"Nabhan","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Faculty of Medicine; Ain Shams University; Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine; Brigham and Women's Hospital, Harvard Medical School; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"10.1002\/14651858.CD014541.pub2-BIB0001|cit1","unstructured":"Multicenter, rAndomized, parallel Group Efficacy superiority study in hospitalized medically iLL patients comparing rivaroxabAN with enoxaparin - MAGELLAN www.clinicaltrialsregister.eu\/ctr-search\/trial\/2007-004614-14\/IT"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0002|cit2","first-page":"66","article-title":"The MAGELLAN study methodology: rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in hospitalized medically ill patients","volume":"95","author":"Cohen","year":"2010","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014541.pub2-BIB0003|cit3","first-page":"961","article-title":"Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: analysis of factors contributing to benefit and risk in MAGELLAN","volume":"9","author":"Cohen","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1538-7836.2011.04380_1.x","article-title":"Rivaroxaban vs enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: MAGELLAN subgroup analyses","volume":"9","author":"Cohen","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s11239-011-0549-x","article-title":"Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol","volume":"31","author":"Cohen","year":"2011","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"6","key":"10.1002\/14651858.CD014541.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD014541.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood.V116.21.3331.3331","article-title":"Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: MAGELLAN study methodology","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/jth.12515","article-title":"D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial","volume":"12","author":"Cohen","year":"2014","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD014541.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1111\/jth.14146","article-title":"Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study","volume":"16","author":"Cohoon","year":"2018","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0010|cit10","unstructured":"Venous Thromboembolic Event (VTE) prophylaxis in medically ill patients (MAGELLAN) classic.clinicaltrials.gov\/ct2\/show\/NCT00571649"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"107602961988602","DOI":"10.1177\/1076029619886022","article-title":"Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study","volume":"25","author":"Spyropoulos","year":"2019","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1182\/blood-2019-122930","article-title":"Association of bleeding severity with mortality with in-hospital and extended thromboprophylaxis in the medically ill in the MAGELLAN Trial","volume":"134","author":"Spyropoulos","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s11239-019-01943-5","article-title":"Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial","volume":"49","author":"Ageno","year":"2020","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"12","key":"10.1002\/14651858.CD014541.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1111\/jth.14600","article-title":"Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more","volume":"17","author":"Ageno","year":"2019","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"Suppl E","key":"10.1002\/14651858.CD014541.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1093\/eurheartj\/suy017","article-title":"Betrixaban for prevention of venous thromboembolism in acute medically ill patients","volume":"20","author":"Beyer-Westendorf","year":"2018","journal-title":"European Heart Journal Supplements"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/eurheartj\/ehy563.4321","article-title":"Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial","volume":"39","author":"Chi","year":"2018","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1161\/CIRCULATIONAHA.117.031187","article-title":"Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients","volume":"137","author":"Chi","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD014541.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ahj.2013.11.006","article-title":"The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study","volume":"167","author":"Cohen","year":"2014","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD014541.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/eurheartj\/ehx502.P1732","article-title":"P1732 Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy","volume":"38","author":"Gibson","year":"2017","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD014541.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/CIRCULATIONAHA.116.025427","article-title":"Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"A19208","DOI":"10.1161\/circ.134.suppl_1.19208","article-title":"Abstract 19208. Extended duration betrixaban reduces the risk of stroke vs standard dose enoxaparin among hospitalized medically ill patients: an APEX Substudy","volume":"134","author":"Gibson","year":"2016","journal-title":"Circulation"},{"issue":"S1","key":"10.1002\/14651858.CD014541.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jth.13325","article-title":"CA02 VTE prevention in acutely ill medical patients with extended duration betrixaban - a multicenter, randomized, active-controlled efficacy and safety study comparing extended duration betrixaban with standard of care enoxaparin","volume":"14","author":"Gibson","year":"2016","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD014541.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"e006015","DOI":"10.1161\/JAHA.117.006015","article-title":"Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX Trial substudy","volume":"6","author":"Gibson","year":"2017","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ahj.2017.12.015","article-title":"Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients","volume":"198","author":"Gibson","year":"2018","journal-title":"American Heart Journal"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD014541.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0735-1097(17)35248-8","article-title":"Extended duration betrixaban reduces the risk of venous thromboembolism versus standard duration enoxaparin in the post parenteral period among hospitalized medically ill patients","volume":"69","author":"Gibson","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"A20322","DOI":"10.1161\/circ.136.suppl_1.20322","article-title":"Abstract 20322. Extended-duration betrixaban reduces the risk of venous thromboembolism-related rehospitalization among acutely ill hospitalized medical patients: an APEX trial substudy","volume":"136","author":"Hi","year":"2017","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"A20393","DOI":"10.1161\/circ.136.suppl_1.20393","article-title":"Abstract 20393. Full-dose betrixaban reduces venous thromboembolism-related mortality: an APEX Trial Substudy","volume":"136","author":"Ibson","year":"2017","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"A19325","DOI":"10.1161\/circ.134.suppl_1.19325","article-title":"Abstract 19325. Betrixaban reduces the burden of multiple symptomatic venous thromboembolic events in the APEX Trial","volume":"134","author":"Jain","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/eurheartj\/ehy564.P251","article-title":"P251 Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial","volume":"39","author":"Kalayci","year":"2018","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD014541.pub2-BIB0031|cit31","first-page":"2366","article-title":"Extended anticoagulant prophylaxis in initially hospitalized medically ill patients: results of the ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial","volume":"124","author":"Goldhaber","year":"2011","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD014541.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0033|cit33","unstructured":"Study of apixaban for the prevention of rhrombosis-related events in patients with acute medical illness clinicaltrials.gov\/show\/NCT00457002"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0034|cit34","first-page":"Abstract OC397","article-title":"Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with prolonged periods of immobilisation: the EXCLAIM study","volume":"1","author":"Hull","year":"2003","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility","volume":"153","author":"Hull","year":"2010","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11239-006-7732-5","article-title":"Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study","volume":"22","author":"Hull","year":"2006","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014541.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"O","DOI":"10.1111\/j.1538-7836.2007.tb00002.x","article-title":"Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study","volume":"5","author":"Hull","year":"2007","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0038|cit38","unstructured":"EXCLAIM: extended prophylaxis for venous thromboembolism (VTE) in acutely ill medical patients with prolonged immobilization clinicaltrials.gov\/show\/NCT00077753"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood.V110.11.1870.1870","article-title":"Extended-duration enoxaparin for venous thromboembolism prophylaxis in acutely ill medical patients: an evaluation of the EXCLAIM Study based on a recently recommended composite efficacy endpoint","volume":"110","author":"Schellong","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1182\/blood.V110.11.1863.1863","article-title":"Consistent venous thromboembolism risk reduction by extended- versus standard-duration enoxaparin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM Study","volume":"110","author":"Tapson","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"249\u201351","DOI":"10.1161\/STROKEAHA.112.659797","article-title":"Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM Study","volume":"44","author":"Turpie","year":"2013","journal-title":"Stroke"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood.V112.11.433.433","article-title":"Venous thromboembolism risk in stroke patients receiving extended-duration enoxaparin prophylaxis: sub-analysis of the EXCLAIM Study","volume":"112","author":"Turpie","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1182\/blood.V110.11.1862.1862","article-title":"The effects of the degree of mobility reduction and prespecified risk factors on venous thromboembolism rates in acutely ill medical patients in the EXCLAIM Study","volume":"110","author":"Yusen","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood.V112.11.438.438","article-title":"The impact of age on the efficacy and safety of extended-duration thromboprophylaxis in acutely ill medical patients with recent immobility: a sub-group analysis from the EXCLAIM Study","volume":"112","author":"Yusen","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0045|cit45","first-page":"31","article-title":"Two models of thromboprophylaxis in acutely ill medical inpatients","volume":"117","author":"Luba","year":"2007","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0046|cit46","unstructured":"Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: the MICHELLE Trial clinicaltrials.gov\/show\/NCT04662684"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ahj.2021.08.016","article-title":"Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE Trial","volume":"242","author":"Ramacciotti","year":"2021","journal-title":"American Heart Journal"},{"issue":"10319","key":"10.1002\/14651858.CD014541.pub2-BIB0048|cit48","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(21)02392-8","article-title":"Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial","volume":"399","author":"Ramacciotti","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD014541.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1160\/TH15-09-0756","article-title":"The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications","volume":"115","author":"Raksob","year":"2016","journal-title":"Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0050|cit50","first-page":"757","article-title":"Benefit-risk assessment of 10 mg daily rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"3","author":"Raskob","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0051|cit51","first-page":"758","article-title":"Extended-duration thromboprophylaxis with rivaroxaban reduces the risk of major and fatal vascular events in hospitalized medically ill patients","volume":"3","author":"Spyropoulos","year":"2019","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"25","key":"10.1002\/14651858.CD014541.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.jacc.2020.04.071","article-title":"Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients","volume":"75","author":"Spyropoulos","year":"2020","journal-title":"Journal of the American College of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD014541.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD014541.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jth.13783","article-title":"Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis","volume":"15","author":"Chi","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00134-019-05565-6","article-title":"Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy","volume":"45","author":"Chi","year":"2019","journal-title":"Intensive Care Medicine"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0056|cit56","unstructured":"Prophylaxis of venous thromboembolism in advanced lung cancer (PROVE) clinicaltrials.gov\/show\/NCT03090880"},{"issue":"12","key":"10.1002\/14651858.CD014541.pub2-BIB0057|cit57","first-page":"646","article-title":"Results of the EXCLAIM study: medical patients profit significantly from extended-duration thromboprophylxis","volume":"58","author":"Burian","year":"2007","journal-title":"Die Medizinische Welt"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0058|cit58","first-page":"236","article-title":"MARINER study","volume":"18","author":"Spinarova","year":"2019","journal-title":"Intervencni a Akutni Kardiologie"},{"issue":"5","key":"10.1002\/14651858.CD014541.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003747.pub4","article-title":"Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction)","author":"Alikhan","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD014541.pub2-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/jhm.1002","article-title":"Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients","volume":"7","author":"Amin","year":"2012","journal-title":"Journal of Hospital Medicine"},{"issue":"23 (Suppl 1)","key":"10.1002\/14651858.CD014541.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"I9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"issue":"23","key":"10.1002\/14651858.CD014541.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Advances"},{"issue":"7","key":"10.1002\/14651858.CD014541.pub2-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002001.pub3","article-title":"Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism","author":"Andras","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7454","key":"10.1002\/14651858.CD014541.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"e1002797","DOI":"10.1371\/journal.pmed.1002797","article-title":"Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: a trial sequential and cumulative meta-analysis","volume":"16","author":"Bajaj","year":"2019","journal-title":"PLoS Medicine"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score","volume":"8","author":"Barbar","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"e351S","DOI":"10.1378\/chest.11-2299","article-title":"Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD014541.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/s0741-5214(96)70007-1","article-title":"Progression of superficial venous thrombosis to deep vein thrombosis","volume":"24","author":"Chengelis","year":"1996","journal-title":"Journal of Vascular Surgery"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0069|cit69","first-page":"750","article-title":"Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients","volume":"94","author":"Cohen","year":"2005","journal-title":"Thrombosis and Haemostasis"},{"issue":"6","key":"10.1002\/14651858.CD014541.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMc1303641","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD014541.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJMoa1601747","article-title":"Extended thromboprophylaxis with betrixaban in acutely ill medical patients","volume":"375","author":"Cohen","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0072|cit72","unstructured":"Covidence Systematic Review software Veritas Health Innovation 2023"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0073|cit73","unstructured":"Cumpston M Lasserson T Chandler J Page MJ Chapter III: Reporting the review. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archives\/v6.3 2022"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis","volume":"44","author":"Cushman","year":"2007","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0075|cit75","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"03","key":"10.1002\/14651858.CD014541.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1160\/TH16-08-0595","article-title":"Efficacy and safety of extended thromboprophylaxis for medically ill patients","volume":"117","author":"Dentali","year":"2017","journal-title":"Thrombosis and Haemostasis"},{"issue":"7109","key":"10.1002\/14651858.CD014541.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"8","key":"10.1002\/14651858.CD014541.pub2-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004318.pub5","article-title":"Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery","author":"Felder","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD014541.pub2-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004179.pub2","article-title":"Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair","author":"Forster","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"01","key":"10.1002\/14651858.CD014541.pub2-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1055\/s-0037-1603929","article-title":"The IMPROVEDD VTE risk score: incorporation of D-Dimer into the IMPROVE score to improve venous thromboembolism risk stratification","volume":"01","author":"Gibson","year":"2017","journal-title":"TH Open: Companion Journal to Thrombosis and Haemostasis"},{"issue":"23","key":"10.1002\/14651858.CD014541.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD014541.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0084|cit84","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool McMaster University and Evidence Prime 2024"},{"issue":"(2 Suppl)","key":"10.1002\/14651858.CD014541.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD014541.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/ATVBAHA.108.162545","article-title":"The epidemiology of venous thromboembolism in the community","volume":"28","author":"Heit","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nature Reviews Cardiology"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0088|cit88","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0089|cit89","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-153-1-201007060-00004","article-title":"Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial","volume":"153","author":"Hull","year":"2010","journal-title":"Annals of Intrenal Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD014541.pub2-BIB0091|cit91","doi-asserted-by":"publisher","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"issue":"9920","key":"10.1002\/14651858.CD014541.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(13)61902-9","article-title":"Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0093|cit93","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005258.pub4","article-title":"Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism","author":"Kakkos","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD014541.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"595\u2013605","DOI":"10.1111\/jth.12529","article-title":"Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis","volume":"12","author":"Lapner","year":"2014","journal-title":"Jounral of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0096|cit96","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"3","key":"10.1002\/14651858.CD014541.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"291\u2013301","DOI":"10.1007\/s11239-016-1461-1","article-title":"Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Liew","year":"2017","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"4","key":"10.1002\/14651858.CD014541.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41569-022-00787-6","article-title":"Epidemiology and prevention of venous thromboembolism","volume":"20","author":"Lutsey","year":"2022","journal-title":"Nature Reviews. Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1160\/TH12-03-0162","article-title":"Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates","volume":"108","author":"Mahan","year":"2012","journal-title":"Thrombosis and Haemostasis"},{"issue":"11","key":"10.1002\/14651858.CD014541.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1111\/j.1538-7836.2004.01012.x","article-title":"The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry","volume":"2","author":"Monreal","year":"2004","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"h2039","DOI":"10.1136\/bmj.h2039","article-title":"Superficial thrombophlebitis (superficial venous thrombosis)","volume":"350","author":"Nasr","year":"2015","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0102|cit102","unstructured":"National Clinical Guideline Centre Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guideline. Methods, evidence and recommendations www.nice.org.uk\/guidance\/cg144\/evidence\/cg144-venous-thromboembolic-diseases-full-guideline3"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0103|cit103","unstructured":"National Clinical Guideline Centre Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline (NG89) www.nice.org.uk\/guidance\/ng89"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1378\/chest.07-0430","article-title":"Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis","volume":"132","author":"Piazza","year":"2007","journal-title":"Chest"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0106|cit106","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"12","key":"10.1002\/14651858.CD014541.pub2-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001484.pub3","article-title":"Graduated compression stockings for prevention of deep vein thrombosis","author":"Sachdeva","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"22","key":"10.1002\/14651858.CD014541.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1182\/bloodadvances.2018022954","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and non-hospitalized medical patients","volume":"2","author":"Sch\u00fcnemann","year":"2018","journal-title":"Blood Advances"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0110|cit110","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"12","key":"10.1002\/14651858.CD014541.pub2-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/j.1538-7836.2012.04874.x","article-title":"Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?","volume":"10","author":"Sharma","year":"2012","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"14","key":"10.1002\/14651858.CD014541.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/archinte.167.14.1471","article-title":"Venous thromboembolism in the outpatient setting","volume":"167","author":"Spencer","year":"2007","journal-title":"Archives of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014541.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"706\u201314","DOI":"10.1378\/chest.10-1944","article-title":"Predictive and associative models to identify hospitalized medical patients at risk for VTE","volume":"140","author":"Spyropoulos","year":"2011","journal-title":"Chest"},{"issue":"12","key":"10.1002\/14651858.CD014541.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","article-title":"Rivaroxaban for thromboprophylaxis after hospitalization for medical illness","volume":"379","author":"Spyropoulos","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"107602961988602","DOI":"10.1177\/1076029619886022","article-title":"Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN Study","volume":"25","author":"Spyropoulos","year":"2019","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"1","key":"10.1002\/14651858.CD014541.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1182\/hematology.2022000403","article-title":"To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients","volume":"2022","author":"Spyropoulos","year":"2022","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"9","key":"10.1002\/14651858.CD014541.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"1662\u201370","DOI":"10.1160\/TH17-03-0168","article-title":"New paradigms in venous thromboprophylaxis of medically ill patients","volume":"117","author":"Spyropoulos","year":"2017","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014541.pub2-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10","key":"10.1002\/14651858.CD014541.pub2-BIB0119|cit119","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/CIRCULATIONAHA.114.009107","article-title":"30-year mortality after venous thromboembolism","volume":"130","author":"S\u00f8gaard","year":"2014","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD014541.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circulation Research"},{"issue":"23 Suppl 1","key":"10.1002\/14651858.CD014541.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"I4\u2013I8","DOI":"10.1161\/01.CIR.0000078468.11849.66","article-title":"The epidemiology of venous thromboembolism","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD014541.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/jth.13741","article-title":"Chronic complications of venous thromboembolism","volume":"15","author":"Schernthaner","year":"2017","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"2","key":"10.1002\/14651858.CD014541.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/imj.14417","article-title":"Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials","volume":"50","author":"Zayed","year":"2020","journal-title":"Internal Medicine Journal"},{"issue":"7","key":"10.1002\/14651858.CD014541.pub2-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014541","article-title":"Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients","author":"Kolkailah","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T14:47:44Z","timestamp":1774536464000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014541.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":124,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014541.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}